Clinical trial

Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLC

NCT06890182

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2025-03-01

PhasePHASE2

Study timeline

Study start (estimated)2025-03-01Date precision: month

Registry last updated2025-03-21

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non-small Cell Lung Cancerunresolved

Interventions

Firmonertinib combined with Carboplatin/Cisplatin and PemetrexedDRUG

Sponsors & collaborators

Tianjin Medical University Cancer Institute and Hospitallead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06890182 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.